Study guide
11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
Alabama MPJE Pharmacy Jurisprudence Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Board of Pharmacy Governance & Pharmacist Licensure
1.1 Alabama State Board of Pharmacy: Structure, Powers, Rulemaking & the 2026 Nine-Member Board 1.2 Pharmacist Licensure Requirements: Examination, Education, Background Check & Reciprocity 1.3 Pharmacy Interns, Externs & Preceptor Requirements: 1,500 Practical Hours & Supervision Standards
2 Chapter 2: Pharmacy Support Personnel, Ratios & Professional Standards
2.1 Pharmacy Technicians: Registration, Qualifications, Scope of Duties & Tiered Ratios 2.2 License Renewal Cycles, Continuing Education (CE) & Inactive Status 2.3 Disciplinary Grounds, Sanctions, Administrative Hearings & Impaired Pharmacist Rehabilitation
3 Chapter 3: Prescribing Authority, Practitioner Scopes & Corresponding Responsibility
3.1 Prescriptive Authority by Profession: Independent vs. Limited Scopes 3.2 Mid-Level Prescribing: PAs, CRNPs, CNMs, QACSC & Limited Purpose Schedule II Permits (LPSP) 3.3 Corresponding Responsibility, Legitimate Medical Purpose & Red Flags for Controlled Substance Diversion
4 Chapter 4: Opioids, Controlled Substance Clinical Safeguards & Naloxone Access
4.1 Opioid Prescribing Standards: ALBME Risk & Abuse Mitigation, MME Thresholds & Pain-Management Registration 4.2 Overdose Prevention: Statewide Naloxone Standing Order, Co-Prescribing & Pharmacist Dispensing Protocols 4.3 Alabama Prescription Drug Monitoring Program (PDMP): Dispenser Daily Reporting & Prescriber Query Mandates
5 Chapter 5: Clinical Services, Immunizations & Collaborative Practice
5.1 Pharmacist Immunization Authority, Protocols & Training Standards 5.2 Collaborative Drug Therapy Management (CDTM) & Collaborative Practice Agreements 5.3 Patient Counseling & Prospective Drug Utilization Review (DUR) Standards
6 Chapter 6: Prescription Validity, Electronic Prescribing & Security Standards
6.1 Prescription Form Validity: Written, Oral/Telephone & Facsimile Requirements 6.2 Electronic Prescribing & Electronic Prescriptions for Controlled Substances (EPCS) 6.3 Alabama Generic Drug Substitution: Two-Signature Line Law & Therapeutic Equivalence
7 Chapter 7: Prescription Processing, Labeling, Packaging & Emergency Dispensing
7.1 Prescription Labeling Standards & Expiration / Beyond-Use Dating 7.2 Federal Packaging Mandates: Poison Prevention Packaging Act (PPPA) & Child-Resistant Containers 7.3 Emergency Prescription Dispensing: 72-Hour Supply Rule & Disaster Provisions 7.4 Partial Filling of Prescriptions: Non-Controlled, Schedule II & Schedules III–V
8 Chapter 8: Prescription Transfers, Delivery & Remote Pharmacy Services
8.1 Prescription Transfer Rules: Non-Controlled vs. Controlled Substances 8.2 Prescription Delivery, Mail-Order Distribution & Out-of-State Permits 8.3 Patient Records, Confidentiality & Permitted Health Information Disclosures 8.4 Remote Pharmacist Work, Off-Site Order Entry & Off-Site Vaccine Order Processing
9 Chapter 9: Pharmacy Facility Standards, Security & Operational Supervision
9.1 Pharmacy Facility Permits: Application, Inspection, Renewal & Change of Ownership 9.2 Prescription Department Technical Equipment, References & Storage Standards 9.3 Pharmacy Security, Keys & Controlled Access Standards 9.4 Supervising Pharmacist Responsibilities & Temporary Absence
10 Chapter 10: Controlled Substances: Scheduling, Ordering, Inventory & Recordkeeping
10.1 Controlled Substance Scheduling: Federal Framework & Alabama State Variations 10.2 Controlled Substance Ordering & Procurement: DEA Form 222, CSOS & Invoicing 10.3 Controlled Substance Inventory Standards: Alabama Annual Inventory on January 15 10.4 Controlled Substance Records, 2-Year Retention & Filing Systems 10.5 Drug Distribution & Supply-Chain Security: DSCSA, Wholesale Distribution & Alabama Permits
11 Chapter 11: Controlled Substance Diversion Control, Disposal & Precursor Regulation
11.1 Theft and Loss of Controlled Substances: DEA Form 106 & Alabama Board Reporting Requirements 11.2 Controlled Substance Disposal, Destruction & Reverse Distribution 11.3 Ephedrine and Pseudoephedrine Sales Restrictions: Federal & Alabama Law 11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
12 Chapter 12: Compounding Standards, Institutional Practice & Medication Safety
12.1 Non-Sterile Compounding Standards: USP <795>, Beyond-Use Dating & Alabama Standards 12.2 Sterile Compounding & Hazardous Drug Handling: USP <797>, USP <800> & Facility Requirements 12.3 Institutional Pharmacy Practice: Absence of Pharmacist, Night Cabinets, Stat Cabinets & Emergency Kits 12.4 Medication Safety, Drug Recalls (Classes I-III), Adulteration, Misbranding & Return/Reuse Prohibitions
11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
Key Takeaways Explain This Topic AI
The Drug Facts label required by 21 C.F.R. § 201.66 must present Active ingredients, Purpose, Uses, Warnings, Directions, Other information, and Inactive ingredients in that fixed order, with a Questions? contact.
Ala. Admin. Code r. 680-X-2-.04(2) requires every Alabama community pharmacy to keep an exempt narcotic register on hand, the bound record for Schedule V products sold without a prescription.
Under 21 C.F.R. § 1306.26 a Schedule V exempt narcotic may be sold without a prescription only by a pharmacist, to a purchaser at least 18 years old who presents identification, limited to 240 mL or 48 dosage units of an opium-containing preparation and 120 mL or 24 dosage units of any other controlled substance in a 48-hour period.
Syringes may be sold in Alabama without a prescription, and the pharmacist retains professional discretion to decline a sale.
A Risk Evaluation and Mitigation Strategy with Elements To Assure Safe Use can require prescriber certification, pharmacy certification, patient enrollment, and documentation of safe-use conditions before dispensing; a pharmacy that is not certified cannot lawfully dispense the product regardless of the prescription’s validity.
Last updated: September 2026
11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution
Important
Core Exam Concept : The MPJE Competency Statements devote an entire sub-area to non-prescription products — their dispensing or administration, their labeling, their packaging and repackaging, and the sale of restricted non-prescription drugs. Candidates who study only prescription law leave that ground uncovered. A second, related area asks about requirements for drug uses, limitations, or restrictions , which is where REMS programs live. This section closes both.
1. The OTC Monograph System and the Drug Facts Label
A drug may be sold over the counter when its conditions of use are recognized as generally recognized as safe and effective (GRASE) — historically through an OTC monograph , and since the CARES Act of 2020 through the reformed OTC monograph order process — or when FDA approves an Rx-to-OTC switch through an NDA.
21 C.F.R. § 201.66 prescribes the standardized Drug Facts panel. The order is fixed and is itself examinable: +-----------------------------------------------------------------------------------------+
- | DRUG FACTS PANEL -- MANDATORY ORDER |
- +-----------------------------------------------------------------------------------------+
- | 1. Active ingredient(s) ... with the amount per dosage unit |
- | 2. Purpose ... the general pharmacologic category |
- | 3. Uses ... the indications |
- | 4. Warnings ... in a fixed internal order: Do not use / Ask a doctor / |
- | Ask a doctor or pharmacist before use / When using this |
- | product / Stop use and ask a doctor / pregnancy-nursing / |
- | Keep out of reach of children |
- | 5. Directions ... dosage by age group |
- | 6. Other information ... e.g., storage, sodium content |
- | 7. Inactive ingredients ... alphabetical |
- | 8. Questions or comments?... a telephone number for the responsible firm |
- +-----------------------------------------------------------------------------------------+
"Keep out of reach of children" is not optional , and neither is the accidental-overdose instruction to contact a poison control center — which pairs with the requirement that the poison control telephone number be posted in the prescription department.
Tamper-Evident Packaging (21 C.F.R. § 211.132) : OTC drug products for retail sale must use tamper-evident packaging, and the labeling must describe the safety feature so a consumer can recognize tampering. Two-piece hard gelatin capsules require two tamper-evident features unless sealed.
2. Repackaging and Labeling Non-Prescription Products
When a pharmacy repackages an OTC product — breaking a bulk container into smaller units for sale, or preparing a unit-dose for an institution — it takes on manufacturer-style labeling duties.
- Situation Required Labeling
- OTC sold in the manufacturer's container The manufacturer's Drug Facts panel suffices
OTC repackaged by the pharmacy for retail sale Name and address of the repackager, product name, active ingredients and amounts, quantity, lot number, expiration date, and the required warnings
OTC dispensed against a prescription The product becomes a dispensed prescription and takes the prescription label required by Ala. Admin. Code r. 680-X-2-.13 — pharmacy name and address, prescriber's directions for use, drug name as dispensed, and strength per dosage unit
OTC repackaged as institutional unit-dose Drug name, strength, lot number, and expiration date legible on each individual unit
Note
The insurance question is a labeling question. Patients frequently ask for a prescription for an OTC product so a plan will pay. Once the pharmacist dispenses it against that prescription, the container carries a prescription label under r. 680-X-2-.13, is entered in the prescription record system under r. 680-X-2-.15, and is subject to the counseling offer under r. 680-X-2-.21. It is no longer an over-the-counter transaction.
- 3. Restricted Non-Prescription Sales
- Schedule V Exempt Narcotics (21 C.F.R. § 1306.26)
A controlled substance in Schedule V that is not a prescription drug may be sold at retail without a prescription only if all of the following hold:
The sale is made by a pharmacist — the pharmacist may delegate the money-and-bag mechanics to a non-pharmacist after making the actual sale, but the professional decision cannot be delegated;
Not more than 240 mL (8 ounces) or 48 dosage units of an opium-containing substance, and not more than 120 mL (4 ounces) or 24 dosage units of any other controlled substance, are sold to the same purchaser in any 48-hour period ;
- The purchaser is at least 18 years of age ;
- The pharmacist requires suitable identification from a purchaser not known to the pharmacist; and
A bound record book is maintained containing the purchaser's name and address, the name and quantity of the substance, the date, and the name or initials of the dispensing pharmacist. That book must be kept for two years .
Alabama supplies the register expressly : under Ala. Admin. Code r. 680-X-2-.04(2) , "community pharmacies shall have on hand an exempt narcotic register ." Its absence is an independent inspection finding, separate from any question about whether a sale occurred.
Ephedrine and Pseudoephedrine
Covered in detail in section 11.3. In summary, Alabama restricts sales to pharmacies licensed by the Board, requires the product to be stored behind the pharmacy counter , limits a purchaser to 3.6 grams per calendar day and 7.5 grams per 30 days — stricter than the federal 9-gram monthly figure — requires the purchaser to be at least 18 with a valid government-issued ID, and requires electronic submission to NPLEx before the sale.
Syringes and Needles
The Alabama Board of Pharmacy's published position is that syringes may be sold in Alabama without a prescription . Unlike states with paraphernalia statutes or age restrictions on syringe sales, Alabama permits the sale, and the pharmacist retains professional discretion to decline a sale they judge inappropriate. That discretion is the practice point: the absence of a legal bar is not a duty to sell.
Naloxone
Available through the statewide standing order discussed in section 4.2, which functions as a prescription rather than as an over-the-counter sale for the products it covers, even though FDA has since approved OTC naloxone nasal spray.
4. Restricted Distribution of Prescription Drugs: REMS
The blueprint's "requirements for drug uses, limitations, or restrictions" reaches the FDA's Risk Evaluation and Mitigation Strategy authority under the Food and Drug Administration Amendments Act of 2007 .
REMS Component What It Means Pharmacy Consequence
Medication Guide / Patient Package Insert Written information the patient must receive Must be distributed each time the drug is dispensed
Communication Plan Directed at healthcare providers No pharmacy gate, but affects counseling
Elements To Assure Safe Use (ETASU) The restrictive tier May require prescriber certification , pharmacy certification , patient enrollment/monitoring , dispensing only in certain settings , or documentation of safe-use conditions before each dispense
Implementation System Sponsor monitoring of ETASU compliance Pharmacy audits and data submission
Caution
A valid prescription is not sufficient when ETASU applies. If the pharmacy is not certified in the program, or the prescriber is not certified, or the patient is not enrolled and current on required monitoring, the pharmacy cannot lawfully dispense — no matter how facially perfect the prescription is. Familiar ETASU programs include clozapine (absolute neutrophil count monitoring), isotretinoin (iPLEDGE) (pregnancy testing and dual contraception), thalidomide and lenalidomide , sodium oxybate , and mifepristone . The correct pharmacist action when a REMS requirement is unmet is to hold the prescription and resolve the deficiency, not to dispense and document.
Two related restriction mechanisms round out the topic:
Medication Guides (21 C.F.R. Part 208) exist independently of REMS for drug classes with serious risks, and must be provided at each dispensing.
Patient Package Inserts (21 C.F.R. § 310.501, § 310.515) are mandatory for oral contraceptives and estrogen-containing products , and must be dispensed with each fill including refills.